Stock NRIX NURIX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-29 EDT 		5-day change 1st Jan Change
12.47 USD +0.89% Intraday chart for Nurix Therapeutics, Inc. -8.17% +20.83%
04-12 Sector Update: Health Care Stocks Steady Pre-Bell Friday MT
04-12 Sector Update: Health Care MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
NURIX THERAPEUTICS, INC. Stock Nurix Therapeutics, Inc.
+20.83% 733M
C
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.63% 103B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 95.28B
B+
ARGENX SE Stock argenx SE
+1.46% 22.15B
B
BIONTECH SE Stock BioNTech SE
-16.67% 21.02B
B+
GENMAB A/S Stock Genmab A/S
-8.58% 18.15B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 16.73B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.05B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.41% 13.68B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.57% 12.17B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. NRIX Stock
  4. Ratings Nurix Therapeutics, Inc.